CAM
ITCI

Connacht Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Connacht Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,260
Closed -$460K – 99
2023
Q2 		$460K Sell
7,260
-514
-7% -$32K 0.63% 39
2023
Q1 		$421K Buy
7,774
+232
+3% +$11.2K 0.18% 87
2022
Q4 		$399K Sell
7,542
-3,364
-31% -$169K 0.18% 82
2022
Q3 		$507K Buy
+10,906
New +$570K 0.36% 70

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connacht Asset Management's ITCI Position: Q3 2023 in Review

Connacht Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2023, closing a stake of 7,260 shares — an estimated $460K sold.

Connacht Asset Management first reported a position in ITCI in Q3 2022 and held it in 4 quarters. The position peaked at $507K in Q3 2022. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

  • Connacht Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2023 after selling out during the quarter.
  • Connacht Asset Management sold 7,260 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $460K.
  • Connacht Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2022 and held it in 4 quarters.
  • Connacht Asset Management's Intra-Cellular Therapies Inc. position peaked at $507K in Q3 2022.
  • 292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.